Crossmark

Unrecognized mutations in DPYD* 2 A wild-type rectal cancer patients receiving postoperative 5-FU-based chemotherapy - do they have a clinical impact?

Crossref DOI link: https://doi.org/10.1007/s00280-025-04787-4

Published Online: 2025-07-15

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liersch, P.

Dierks, S.

Andag, R.

Liersch, T.

de Boer, C.

Kreutzer, J.

Hille, A.

Sülberg, H.

Leha, A.

Schanz, Julie
Funding

Funding for this research was provided by:

Herzzentrum Göttingen
License Information

Text and Data Mining valid from 2025-07-15

Version of Record valid from 2025-07-15
More Information

Article History

Received: 26 January 2025

Accepted: 16 June 2025

First Online: 15 July 2025

Declarations

:

: All patients were recruited from the prospective clinical GAST-05-phase-II-trial (ISRCTN35198481). The Ethics Committee at the University of Göttingen approved the study (No: 21/11/06), and all patients gave informed consent in written form.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below